Close Menu

NEW YORK (GenomeWeb News) – Rosetta Genomics and its research collaborators have published in the Journal of Clinical Oncology data from a study showing that the same biomarker used in the firm's miRNA-based test for squamous lung cancer provided 96 percent sensitivity.

The study, which was posted online Monday on the journal's website, included 262 patients and was conducted by Rehovot, Israel-based Rosetta and researchers from Columbia University, NYU Cancer Institute, and Sheba Medical Center.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.

An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.

Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.